IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+35.4%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$328M
AUM Growth
+$328M
(+46%)
Cap. Flow
+$56M
Cap. Flow
% of AUM
17.07%
Top 10 Holdings %
Top 10 Hldgs %
34.61%
Holding
78
New
27
Increased
13
Reduced
13
Closed
18
Top Buys
| 1 |
LHCG
LHC Group LLC
LHCG
|
$13.1M |
| 2 |
Charles River Laboratories
CRL
|
$9.59M |
| 3 |
Cencora
COR
|
$9.07M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.65M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.48M |
Top Sells
| 1 |
Medtronic
MDT
|
$10.4M |
| 2 |
Centene
CNC
|
$10.1M |
| 3 |
Encompass Health
EHC
|
$7.36M |
| 4 |
Masimo
MASI
|
$6.2M |
| 5 |
Novartis
NVS
|
$5.77M |
Sector Composition
| 1 | Healthcare | 88.41% |
| 2 | Energy | 6.64% |
| 3 | Technology | 0.85% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LHCG
1
DELISTED
LHC Group LLC
LHCG
| $21.8M | 6.53% | 125,000 +75,000 | +150% | +$13.1M |
|
2
Quest Diagnostics
DGX
$20.3B
| $13.7M | 4.1% | 120,000 | – | – |
|
3
Bristol-Myers Squibb
BMY
$96B
| $11.8M | 3.52% | 200,000 +25,000 | +14% | +$1.47M |
|
|
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11M | 3.3% | 175,000 +65,000 | +59% | +$4.09M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.87M | 2.95% | 80,000 -30,000 | -27% | -$3.7M |
|
|
6
Charles River Laboratories
CRL
$8.04B
| $9.59M | 2.87% | +55,000 | New | +$9.59M |
|
|
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $9.2M | 2.76% | 75,000 | – | – |
|
|
8
Cencora
COR
$56.5B
| $9.07M | 2.72% | +90,000 | New | +$9.07M |
|
|
NVRO
9
DELISTED
NEVRO CORP.
NVRO
| $8.96M | 2.68% | 75,000 +35,000 | +88% | +$4.18M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $8.63M | 2.58% | 150,000 -40,000 | -21% | -$2.3M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $8.58M | 2.57% | 110,000 +50,000 | +83% | +$3.9M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $8.11M | 2.43% | 195,000 +25,000 | +15% | +$1.04M |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $8.02M | 2.4% | 150,000 | – | – |
|
14
Cytokinetics
CYTK
$4.23B
| $8.01M | 2.4% | 340,000 +20,000 | +6% | +$471K |
|
15
Danaher
DHR
$147B
| $7.96M | 2.38% | 45,000 -5,000 | -10% | -$884K |
|
16
Humana
HUM
$36.5B
| $7.76M | 2.32% | 20,000 +15,000 | +300% | +$5.82M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.65M | 2.29% | +45,000 | New | +$7.65M |
|
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.48M | 2.24% | +12,000 | New | +$7.48M |
|
|
CTLT
19
DELISTED
CATALENT, INC.
CTLT
| $7.33M | 2.2% | 100,000 -50,000 | -33% | -$3.67M |
|
20
Molina Healthcare
MOH
$9.8B
| $7.12M | 2.13% | +40,000 | New | +$7.12M |
|
|
NUVA
21
DELISTED
NuVasive, Inc.
NUVA
| $6.96M | 2.08% | +125,000 | New | +$6.96M |
|
22
AstraZeneca
AZN
$248B
| $6.61M | 1.98% | 125,000 -65,000 | -34% | -$3.44M |
|
23
DexCom
DXCM
$29.5B
| $6.08M | 1.82% | +15,000 | New | +$6.08M |
|
24
Universal Health Services
UHS
$11.6B
| $6.04M | 1.81% | +65,000 | New | +$6.04M |
|
25
Amgen
AMGN
$155B
| $5.9M | 1.77% | +25,000 | New | +$5.9M |
|